Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Aliskiren + Hydrochlorothiazide (± Amlodipine 5 mg) in Patients With Moderate Hypertension

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria for Core Study:~- Patients with mean sitting diastolic blood pressure ≥ 100 mmHg and \< 110 mmHg~Inclusion criteria for the Extension:~- msSBP ≥ 140 mm Hg and/or msDBP ≥ 90 mm Hg at Visit 5 of the core study~Exclusion Criteria for Core Study:~* Patients with mean diastolic blood pressure ≥ 110 mmHg or mean systolic blood pressure ≥ 180 mmHg~* Patients with prior stroke, hypertensive encephalopathy or heart attack~* Patients with type 1 diabetes mellitus~* Patients with type 2 diabetes mellitus with poor glucose control~Exclusion criteria for the Extension:~* Premature discontinuation in the core study or failure to comply with the core study protocol~* History of hypersensitivity to any of the study drugs or to drugs with similar chemical structures, known or suspected contraindications to diuretics as described in the SmPC (particularly amlodipine 5 mg), e.g. severe hypotension, shock - including cardiogenic shock, obstructions impairing the flow out of the left ventricle (e.g. significant aortic stenosis)~* Any patient that the investigator decides should not participate in the extension study for medical reasons~Other protocol-defined inclusion/exclusion criteria applied to the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Candesartan+HCTZ, aliskiren+HCTZ, aliskiren+HCTZ+amlodipine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).